Corcept Therapeutics (HTD) Stock Statistics & Valuation Metrics

Corcept Therapeutics has a market cap or net worth of CHF7.59B. The enterprise value is $8.68B.

Corcept Therapeutics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Corcept Therapeutics’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 6.67%.

The current PE Ratio of Corcept Therapeutics is 194.0. Corcept Therapeutics’s PEG ratio is -1.24.

In the last 12 months, Corcept Therapeutics had revenue of 761.41M and earned 99.65M in profits. Earnings per share was 0.95.

In the last 12 months, operating cash flow was 120.10M and capital expenditures -308.00K, giving a free cash flow of 119.79M billion.

Corcept Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Corcept Therapeutics upcoming earnings date is Aug 5, 2026, TBA (Confirmed).

Corcept Therapeutics as a current ratio of 2.92, with Debt / Equity ratio of 1.51%

In the past 12 months, Corcept Therapeutics has paid -33.19M in taxes.

Corcept Therapeutics EV to EBITDA ratio is 51.20, with an EV/FCF ratio of 24.69.

Corcept Therapeutics has CHF338.18M in cash and marketable securities with CHF9.64M in debt, giving a net cash position of CHF328.55M billion.

Gross margin is 98.25%, with operating margin of 5.88%, and net profit margin of 13.09%.

The average price target for Corcept Therapeutics is CHF79.13, which is 11.43% higher than the current price. The consensus rating is Strong Buy